FDA Expands Leucovorin Approval for Rare Genetic Disorder
The FDA plans to expand leucovorin's approval to treat cerebral folate deficiency, a condition causing autism-like symptoms, excluding autism itself. Previously approved for cancer drug toxicity, the focus remains on evidence-supported use for the rare disorder, despite prior consideration for broader autism use.
The U.S. Food and Drug Administration (FDA) is set to announce an expansion of leucovorin's approval specifically for treating cerebral folate deficiency, a rare genetic condition presenting autism-like symptoms, as reported by the Washington Post.
This decision excludes the broader autism spectrum, despite initial considerations to expand use. Leucovorin, known for counteracting the toxic effects of certain cancer drugs that inhibit folate, will now be used where there is strongest evidence of its efficacy.
The FDA's move follows a systematic review favoring targeted application, even as pediatricians advise caution due to limited support for widespread autistic use. The U.S. Health Department has not commented on this development.
Google News